SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001600620-24-000099
Filing Date
2024-09-12
Accepted
2024-09-12 16:08:25
Documents
15
Period of Report
2024-09-09
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K auph-20240909.htm   iXBRL 8-K 37515
2 EX-3.1 exhibit31arbylawseptember2.htm EX-3.1 247488
3 EX-99.1 exhibit991_bodrestructure.htm EX-99.1 9138
  Complete submission text file 0001600620-24-000099.txt   476805

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT auph-20240909.xsd EX-101.SCH 1932
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT auph-20240909_lab.xml EX-101.LAB 22532
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT auph-20240909_pre.xml EX-101.PRE 13067
17 EXTRACTED XBRL INSTANCE DOCUMENT auph-20240909_htm.xml XML 2819
Mailing Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6
Business Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6 250-744-2487
Aurinia Pharmaceuticals Inc. (Filer) CIK: 0001600620 (see all company filings)

IRS No.: 981231763 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36421 | Film No.: 241295014
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)